[go: up one dir, main page]

AR041136A1 - Pirazolopirimidinas como inhibidores de cinasas dependientes de clclinas - Google Patents

Pirazolopirimidinas como inhibidores de cinasas dependientes de clclinas

Info

Publication number
AR041136A1
AR041136A1 ARP030103191A ARP030103191A AR041136A1 AR 041136 A1 AR041136 A1 AR 041136A1 AR P030103191 A ARP030103191 A AR P030103191A AR P030103191 A ARP030103191 A AR P030103191A AR 041136 A1 AR041136 A1 AR 041136A1
Authority
AR
Argentina
Prior art keywords
alkyl
nr5r10
cycloalkyl
aryl
group
Prior art date
Application number
ARP030103191A
Other languages
English (en)
Original Assignee
Pharmacopeia Drug Discovery
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Drug Discovery, Schering Corp filed Critical Pharmacopeia Drug Discovery
Publication of AR041136A1 publication Critical patent/AR041136A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente proporciona compuestos de pirazolo[1,5-a]pirimidina como inhibidores de cinasas dependientes de ciclina, métodos de preparación de dichos compuestos, composiciones farmacéuticas que contienen uno o más de dichos compuestos, métodos de preparación de formulaciones farmacéuticas que comprenden uno o más de dichos compuestos, y métodos de tratamiento, prevención, inhibición, o mejoría de una o más enfermedades asociadas con las CDK, utilizando dichos compuestos o composiciones farmacéuticas. Reivindicación 1: Un compuesto representado por la fórmula estructural (1), en donde: Q es -S(O2)-, -C(O)- ; R es arilo o heteroarilo, en donde dichos arilo o heteroarilo pueden estar insustituidos, o en forma opcional, sustituidos independientemente con una o más porciones iguales o diferentes, en donde cada porción se selecciona de manera independiente entre el grupo que consiste en halógeno, CN, -OR5, -SR5, -S(O2)R6, -S(O2)NR5R6, -NR5R6, -C(O)NR5R6, CF3, alquilo, arilo y OCF3; R2 se selecciona entre el grupo que comprende CN, NR5R6, -C(O2)R6, -C(O)NR5R6, -OR6, -SR6, -S(O2)R7, -S(O2)NR5R6, -N(R5)S(O2)R7, -N(R5)C(O)R7 y -N(R5)C(O)NR5R6; alquinilo, heteroarilo, CF3, heterociclilo, alquinilalquilo, cicloalquilo, alquilo sustituido con 1 a 6 grupos R9 iguales o diferentes, se seleccionados de manera independiente entre la lista de R9 que se expone a continuación, o es un resto del grupo de fórmula (2); R3 se selecciona entre el grupo que comprende H, halógeno, -NR5R6, -C(O)NR5R6, alquilo, alquinilo, cicloalquilo, arilo, arilalquilo, heterociclilo, heterociclilalquilo, heteroarilo y heteroarilalquilo, o es un resto del grupo de fórmula (3), en donde cada uno de dichos alquilo, cicloalquilo, arilo, arilalquilo, heterociclilo, heterociclilalquilo, heteroarilo y heteroarilalquilo para R3 y las porciones heterociclilo cuyas estructuras se mostraron precedentemente para R3 pueden estar sustituidos o en forma opcional, independientemente sustituidos con una o más porciones iguales o diferentes, en donde cada porción se selecciona en forma independiente entre el grupo que consiste en halógeno, alquilo, arilo, cicloalquilo, CF3, CN, -OCF3,-(CR4R5)nOR5, -OR5, -NR5R6, -(CR4R5)nNR5R6, -C(O2)R5, -C(O)R5, -C(O)NR5R6, -SR6, -S(O2)R6, -S(O2)NR5R6, -N(R5)S(O2)R7, -N(R5)C(O)R7 y -N(R5)C(O)NR5R6; R4 es H, halo o alquilo; R5 es H o alquilo; R6 se selecciona en forma independiente entre el grupo que comprende H, alquilo, arilo, arilalquilo, cicloalquilo, heterociclilo, heterociclilalquilo, heteroarilo y heteroarilalquilo, en donde cada uno de dichos alquilo, arilo, arilalquilo, cicloalquilo, heterociclilo, heterociclilalquilo, heteroarilo, y heteroarilalquilo pueden estar insustituidos u opcionalmente sustituidos con uno o más porciones iguales o diferentes, en donde cada porción se selecciona en forma independiente entre el grupo que comprende halógeno, alquilo, arilo, cicloalquilo, heterociclilalquilo, CF3, OCF3, CN, -OR5, -NR5R10, -N(R5)Boc, -(CR4R5)nOR5, -C(O2)R5, -C(O)R5, -C(O)NR5R10, -SO3H, -SR10, -S(O2)R7, -S(O2)NR5R10, -N(R5)S(O2)R7, -N(R5)C(O)R7 y -N(R5)C(O)NR5R10; R10 se selecciona entre el grupo que consiste en H, alquilo, arilo, arilalquilo, cicloalquilo, heterociclilo, heterociclilalquilo, heteroarilo, y heteroarilalquilo, en donde cada uno de dichos alquilo, arilo, arilalquilo, cicloalquilo, heterociclilo, heterociclilalquilo, heteroarilo, y heteroarilalquilo pueden estar insustituidos u opcionalmente sustituidos con una o más porciones iguales o diferentes, en donde cada porción se selecciona en forma independiente entre el grupo que comprende halógeno, alquilo, arilo, cicloalquilo, heterociclilalquilo, CF3, OCF3, CN, -OR5, -NR4R5, -N(R5)Boc, -(CR4R5)nOR5, -C(O2)R5, -C(O)NR4R5, -C(O)R5, -SO3H, -SR5, -S(O2)R7, -S(O2)NR4R5, -N(R5)S(O2)R7, -N(R5)C(O)R7 y -N(R5)C(O)NR4R5; u opcionalmente, (i) R5 y R10 en la porción -NR5R10, o (ii) R5 y R6 en la porción -NR5R6 pueden unirse para formar una porción cicloalquilo o heterociclilo, en donde cada porción cicloalquilo o heterociclilo está insustituida o en forma opcional, independientemente sustituida con uno o más grupos R9; R7 se selecciona entre el grupo que consiste en alquilo, cicloalquilo, arilo, heteroarilo, arilalquilo y heteroarilalquilo, en donde cada uno de dichos alquilo, cicloalquilo, heteroarilalquilo, arilo, heteroarilo y arilalquilo pueden estar insustituidos u opcionalmente sustituidos de manera independiente con uno o más porciones iguales o diferentes, en donde cada porción se selecciona en forma independiente entre el grupo que comprende halógeno, alquilo, arilo, cicloalquilo, CF3, OCF3, CN, -OR5, -NR5R10, -CH2OR5, -C(O2)R5, -C(O)NR5R10, -C(O)R5, -SR10, -S(O2)R10, -S(O2)NR5R10, -N(R5)S(O2)R10, -N(R5)C(O)R10 y -N(R5)C(O)NR5R10; R8 se selecciona entre el grupo que consiste en R6, -C(O)NR5R10, -S(O2)NR5R10, -C(O)R7 y -S(O2)R7; R9 se selecciona entre el grupo que consiste en halógeno, CN, -NR5R10, -C(O2)R6, -C(O)NR5R10, -OR6, -SR6, -S(O2)R7, -S(O2)NR5R10, -N(R5)S(O2)R7, -N(R5)C(O)R7 y -N(R5)C(O)NR5R10; m es 0 a 4; y n es 1 a 4. Reivindicación 30: El método de la reivindicación 29, en donde dicha cinasa dependiente de ciclina es CDK2. Reivindicación 31: El método de la reivindicación 29, en donde dicha enfermedad se selecciona entre el grupo que comprende: cáncer de la vejiga, mama, colon, rinón, hígado, pulmón, cáncer de pulmón de célula pequena, esófago, vesícula biliar, ovario, páncreas, estómago, cervical, tiroides, próstata y piel, incluyendo carcinoma de célula escamosa; leucemia, leucemia del tipo linfocitosis aguda, leucemia de linfoblasto aguda, linfoma de célula B, linfoma de célula T, linfoma de Hodgkins, linfoma no Hodgkins, linfoma de células veleosas y linfoma de Burkett; leucemia mielógena aguda y crónica, síndrome mielodisplástico, leucemia promielocítica; fibrosarcoma, rabdomiosarcoma; astrocitoma, neublastoma, glioma y schwannomas; melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, queratoacantoma, cáncer folicular tiroideo y sarcoma de Kaposi.
ARP030103191A 2002-09-04 2003-09-03 Pirazolopirimidinas como inhibidores de cinasas dependientes de clclinas AR041136A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40799902P 2002-09-04 2002-09-04

Publications (1)

Publication Number Publication Date
AR041136A1 true AR041136A1 (es) 2005-05-04

Family

ID=31978544

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103191A AR041136A1 (es) 2002-09-04 2003-09-03 Pirazolopirimidinas como inhibidores de cinasas dependientes de clclinas

Country Status (20)

Country Link
US (3) US7074924B2 (es)
EP (1) EP1534710B1 (es)
JP (2) JP4700344B2 (es)
KR (1) KR20050057139A (es)
CN (1) CN1701074A (es)
AR (1) AR041136A1 (es)
AT (1) ATE376548T1 (es)
AU (1) AU2003268385B2 (es)
CA (1) CA2497450C (es)
DE (1) DE60317077T2 (es)
ES (1) ES2291665T3 (es)
HK (1) HK1071569A1 (es)
IL (1) IL167088A (es)
MX (1) MXPA05002570A (es)
MY (2) MY141978A (es)
NZ (1) NZ539164A (es)
PE (1) PE20040999A1 (es)
TW (1) TWI335919B (es)
WO (1) WO2004022560A1 (es)
ZA (1) ZA200501852B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
US7074924B2 (en) * 2002-09-04 2006-07-11 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
KR20050115252A (ko) * 2003-02-28 2005-12-07 데이진 화-마 가부시키가이샤 피라졸로[1,5-ａ]피리미딘 유도체
GB0305559D0 (en) * 2003-03-11 2003-04-16 Teijin Ltd Compounds
CA2538026A1 (en) * 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. Crf antagonists and heterobicyclic compounds
PE20051089A1 (es) * 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
WO2006027346A2 (en) 2004-09-06 2006-03-16 Altana Pharma Ag Novel pyrazolopyrimidines
FR2876583B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
EP1922321A1 (en) * 2005-08-09 2008-05-21 Eirx Therapeutics Ltd Pyrazoloý1,5-a¨pyrimidine compounds and pharmaceutical compositions containing them
EP1931641B1 (en) 2005-09-09 2010-08-25 Schering Corporation NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHI
KR20080106226A (ko) * 2006-03-08 2008-12-04 노파르티스 아게 신경계 장애의 치료에 있어서 피라졸로[1,5ａ]피리미딘-7-일 아민 유도체의 용도
WO2007118844A1 (de) * 2006-04-13 2007-10-25 Basf Se Substituierte pyrazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
US8507673B2 (en) * 2008-12-11 2013-08-13 Emory University Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds
EP2417138B1 (en) 2009-04-09 2019-11-27 Merck Sharp & Dohme Corp. Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
BR112012021198B1 (pt) 2010-02-26 2021-12-14 Mitsubishi Tanabe Pharma Corporation Compostos de pirazolopirimidina, composições relacionadas e seu uso como inibidores de pde10
US10953012B2 (en) 2011-04-26 2021-03-23 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014066795A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
PT3486245T (pt) 2012-12-07 2021-07-30 Vertex Pharma 2-amino-n-(piperidin-1-il-piridin-3- il)pirazolo[1,5alfa]pirimidina-3-carboxamida como inibidor da quinase atr
RU2015143517A (ru) * 2013-03-13 2017-04-19 Дженентек, Инк. Пиразолсодержащие соединения и их применения
JP2016512816A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
SG11201604519PA (en) 2013-12-06 2016-07-28 Vertex Pharma 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
JP2017501145A (ja) 2013-12-23 2017-01-12 ノージン ビーブイ Ｃｃｒ９調節因子として有用な化合物
RS60013B1 (sr) 2014-06-05 2020-04-30 Vertex Pharma Radioaktivno obeleženi derivati jedinjenja 2-amino-6-fluoro-n-[5-fluoropiridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida, korisnog kao inhibitora atr kinaze, dobijanje pomenutog jedinjenja i njegovi različiti čvrsti oblici
CA2950780C (en) 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
EP3355926A4 (en) 2015-09-30 2019-08-21 Vertex Pharmaceuticals Inc. METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS
CN108700594B (zh) 2015-11-18 2021-06-29 建新公司 多囊性肾病的生物标志物及其用途
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4116288Y1 (es) 1964-11-07 1966-07-28
JPS6157587A (ja) * 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
CA2107479C (en) 1991-04-22 1997-12-16 Makoto Inoue Pyrazolo[1,5-a]pyrimidine derivatives and anti-inflammatory agent containing the same
JP3275389B2 (ja) * 1991-09-06 2002-04-15 三菱ウェルファーマ株式会社 ４−アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
GB9325074D0 (en) 1993-12-07 1994-02-02 Zeneca Ltd Bicyclic heterocycles
DE69523864T2 (de) 1994-06-21 2002-06-13 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a] PYRIMIDIN-DERIVATE
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
JPH10101672A (ja) * 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) * 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
JPH11292879A (ja) 1998-04-08 1999-10-26 Otsuka Pharmaceut Factory Inc カルボキサミド誘導体
FR2805160B1 (fr) * 2000-02-23 2002-04-05 Oreal Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture
JP2002053466A (ja) * 2000-08-08 2002-02-19 Otsuka Pharmaceut Factory Inc アポトーシス調整剤
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
FR2817469B1 (fr) 2000-12-04 2003-04-18 Oreal Composition de coloration, procede d'obtention et utilisation pour la coloration de fibres keratiniques
AU2002225096B8 (en) 2000-12-20 2006-07-27 Ipsen Pharma S.A.S. Cyclin-dependent kinase (CDK) and glycogen synthase kinase-3 (GSK-3) inhibitors
KR20040097375A (ko) 2002-04-23 2004-11-17 시오노기 앤드 컴파니, 리미티드 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
DE10223917A1 (de) 2002-05-29 2003-12-11 Bayer Cropscience Ag Pyrazolopyrimidine
US7074924B2 (en) * 2002-09-04 2006-07-11 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
JP2010168406A (ja) 2010-08-05
ZA200501852B (en) 2005-09-08
AU2003268385B2 (en) 2006-12-21
AU2003268385A1 (en) 2004-03-29
JP4700344B2 (ja) 2011-06-15
IL167088A (en) 2010-12-30
US7074924B2 (en) 2006-07-11
US20040116442A1 (en) 2004-06-17
US7511049B2 (en) 2009-03-31
DE60317077D1 (de) 2007-12-06
MY141978A (en) 2010-08-16
ATE376548T1 (de) 2007-11-15
US20060173016A1 (en) 2006-08-03
MY137888A (en) 2009-03-31
TW200420564A (en) 2004-10-16
JP2006502161A (ja) 2006-01-19
WO2004022560A9 (en) 2005-07-07
DE60317077T2 (de) 2008-07-24
CA2497450C (en) 2011-05-31
TWI335919B (en) 2011-01-11
WO2004022560A1 (en) 2004-03-18
NZ539164A (en) 2006-04-28
HK1071569A1 (en) 2005-07-22
PE20040999A1 (es) 2004-12-28
EP1534710A1 (en) 2005-06-01
US20070275983A1 (en) 2007-11-29
KR20050057139A (ko) 2005-06-16
US7309705B2 (en) 2007-12-18
EP1534710B1 (en) 2007-10-24
MXPA05002570A (es) 2005-09-08
CN1701074A (zh) 2005-11-23
CA2497450A1 (en) 2004-03-18
ES2291665T3 (es) 2008-03-01

Similar Documents

Publication Publication Date Title
AR041136A1 (es) Pirazolopirimidinas como inhibidores de cinasas dependientes de clclinas
AR041135A1 (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas
AR041133A1 (es) Pirazolopirimidinas como inhibidores de la quinasa dependientes de la ciclina
AR041134A1 (es) Pirazolopirimidinas como inhibidores de la quinasa dependiente de ciclina
AR061072A1 (es) Pirazolo [1,5- a ] pirimidinas
AR041291A1 (es) Imidazopiridinas como inhibidores de quinasa dependientes de ciclina
JP2006507254A5 (es)
CA2682504A1 (en) Aurora kinase modulators and method of use
HRP20070435A2 (en) Tricyclic-nucleoside compounds for treating viral infections
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
DK2305255T3 (da) Arylurinstofforbindelser i kombination med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
CL2004000720A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLIDINA-1,2-DICARBOXILDIFENILAMIDA, INHIBIDORES DE LOS FACTORES DE COAGULACION Xa, VIIa; PROCESO DE PREPARACION; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; KIT FARMACEUTICO; Y SU USO PARA TRATAR TROMBOSIS, INFAR
DK1521754T3 (da) Virale inhibitorer
PE20091371A1 (es) Inhibidores de hsp90
JP2006502161A5 (es)
NZ526703A (en) Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
JP2006503838A5 (es)
GT200500221A (es) Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan.
DK1719773T3 (da) Kondenserede heterotetracykliske forbindelser og anvendelse deraf som HCV-polymeraseinhibitor
NO20060979L (no) Nye tricykliske nukleosider eller nukleotider som terapeutiske midler
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
GEP20247600B (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
CN104321326A (zh) 氨基取代的咪唑并哒嗪
AR053364A1 (es) Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis

Legal Events

Date Code Title Description
FB Suspension of granting procedure